SCHEMBL23217512

SCHEMBL23217512

CC(N)c1nc(-c2cc(COc3ccccc3CC(=O)O)cc3ccoc23)cs1

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CFD P00746 20/20 0.73
TPSB2 P20231 9/20 0.48
F11 P03951 9/20 0.48
PLG P00747 2/20 0.41
PLAU P00749 2/20 0.41
KLKB1 P03952 2/20 0.41
F7 P08709 2/20 0.41
F2 P00734 1/20 0.39
F9 P00740 1/20 0.39
F10 P00742 1/20 0.39
PLAT P00750 1/20 0.39
PTGS1 P23219 1/20 0.39
SLC18A2 Q05940 1/20 0.39
PDE4D Q08499 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29672981 1.00 CFD (0.73) CFDTPSB2F11PLGPLAU
SCHEMBL29672986 1.00 CFD (0.73) CFDTPSB2F11PLGPLAU
SCHEMBL30010280 0.90 CFD (0.60) CFDTPSB2F11
SCHEMBL23217627 0.90 CFD (0.60) CFDTPSB2F11
SCHEMBL29672967 0.85 CFD (0.69) CFDTPSB2F11PLGPLAU
SCHEMBL23217587 0.85 CFD (0.69) CFDTPSB2F11PLGPLAU
SCHEMBL21438021 0.85 CFD (1.00) CFDTPSB2F11PLGPLAU
SCHEMBL23217847 0.84 CFD (0.67) CFDTPSB2F11PLGPLAU
SCHEMBL23217514 0.84 CFD (0.64) CFDTPSB2F11PLGPLAU
SCHEMBL29672984 0.84 CFD (0.67) CFDTPSB2F11PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed